Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Nemluvio

Nemluvio 30 mg powder and solvent for solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 6

HOS-151700 · Präparat HOS-100595

In atopic dermatitis, the long-term safety of nemolizumab is being further assessed in an open-label extension study (ARCADIA LTE) for up to 200 weeks of treatment in adults and adolescents with moderate-to-severe AD. Interim safety data up to 104 weeks were generally consistent with the safety profile observed up to Week 16 in the pivotal studies. In prurigo nodularis, the long-term safety of nemolizumab is being further assessed in an open-label extension study (OLYMPIA LTE) for up to 184 weeks of treatment in adults with moderate-to-severe PN. Interim safety data up to 100 weeks were generally consistent with the safety profile observed up to Week 16 in the pivotal studies.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.